Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23808154 | 0.85 | NPC1 (0.52) | RIPK1POLBNPC1RAB9AMAPT | |
| SCHEMBL23808090 | 0.84 | RIPK1 (0.68) | RIPK1POLBNPC1RAB9AMAPT | |
| SCHEMBL5527901 | 0.84 | POLB (0.82) | RIPK1POLBNPC1RAB9AMAPT | |
| SCHEMBL24351038 | 0.83 | RIPK1 (0.70) | RIPK1POLB | |
| SCHEMBL9370156 | 0.83 | RIPK1 (0.70) | RIPK1POLB | |
| SCHEMBL23808156 | 0.82 | RIPK1 (0.55) | RIPK1POLBNPC1RAB9AMAPT | |
| SCHEMBL23808123 | 0.82 | ALDH1A1 (0.72) | RIPK1POLBNPC1RAB9AMAPT | |
| SCHEMBL27276665 | 0.81 | RIPK1 (0.71) | RIPK1POLB | |
| SCHEMBL23808158 | 0.80 | RIPK1 (0.68) | RIPK1POLBNPC1RAB9AMAPT | |
| SCHEMBL23830945 | 0.80 | RIPK1 (0.65) | RIPK1POLBNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | VORONOI CO., LTD (KR) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284647-A1 | N-(3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYLPHENYL)-5-PHENYL-4,5-DIHYDRO-1H-PYRAZOLE-1-CARBOXAMIDE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR TREATING KINASE-RELATED DISEASES | MYLK3, MINK1, PLK2 | RIPK1 33/4885POLB 1094/4885NPC1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.